Abstract: The present invention relates to, inter alia, engineered bacteria expressing (i) a surface protein, which specifically interacts cell membrane receptors that are exposed to the luminal side of epithelial cells of diseased gastrointestinal tissue and/or epithelial tissue lining the bile duct, pancreatic duct, or common bile duct, etc., and (ii) a detection marker. The engineered bacteria of the present technology are useful for detecting diseased gastrointestinal tissue and/or epithelial tissue lining the bile duct, pancreatic duct, or common bile duct, etc.

Abstract: The present invention provides universal immunotherapy compositions useful for targeted treatment of cancers and other immune disorders.

Abstract: The present invention provides universal immunotherapy compositions useful for targeted treatment of cancers.

Abstract: Disclosed are compositions and methods for treating cancers characterized by the presence of solid tumors, which simultaneously target a plurality of targets on cancer cells using single CAR T construct.

Abstract: The present invention provides universal immunotherapy compositions useful for targeted treatment of cancers. The present invention utilizes in its various aspects, bifunctional compounds or complexes that contain at least two domains. One domain, referred to herein as a targeting moiety, binds an antigen on the surface of a tumor cell. The other domain, referred to herein as a pro-antigen, is designed to be inert to normal (non-diseased) cells and tissues, and to become activated (or “unmasked” or “unaged”) only upon exposure to light of an appropriate wavelength.

Abstract: The present invention provides universal immunotherapy compositions useful for targeted treatment of cancers and other immune disorders.

Abstract: The present invention provides chimeric antigen receptors, cells expressing same and methods of using same for treatment various disorders such as cancer, autoimmune disorders and graft vs host disease.

Abstract: The present invention relates to compositions and methods for identifying, assessing, preventing, and treating cancer and modulating immune responses using SLNCR isoforms.

Abstract: The present invention provides systems and method of identifying optimal Cas9 guide strand targets to activate or repress a gene epigenetically.

Abstract: The present invention provides methods of systems and methods of site specific methylation.

Abstract: The present invention provides reagents such as cells, cell lines, and vectors, that can be used to identify mammalian genes whose expression products (RNA or protein) play a role in RNA interference (RNAi) and/or to identify chemical modulators of RNAi, or for other purposes. The invention further provides a variety of methods for identifying such genes or modulators. In particular, the invention provides a mammalian cell comprising a nucleic acid that encodes a selectable marker and one or more nucleic acid templates for transcription of an RNAi-inducing agent integrated into the genome of the cell, wherein the RNAi-inducing agent reduces expression of the marker and is not naturally found in the cell. Additional cells and cell lines comprising nucleic acids that encode one or more additional markers are also provided. According to certain of the inventive methods cells such as these are mutagenized, transfected or infected with a library of genetic suppressor elements, or contacted with a test compound.